Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
Inhibrx Reports First Quarter 2026 Financial Results
04:02pm, Thursday, 14'th May 2026
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical comp
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
01:57pm, Monday, 11'th May 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
12:09pm, Monday, 11'th May 2026
Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Ch
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab co
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
04:00pm, Friday, 08'th May 2026
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
10:36am, Thursday, 23'rd Apr 2026
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
05:36pm, Wednesday, 22'nd Apr 2026
Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart's Phase 2 data in chondrosarcoma showed a 52% r
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
02:20pm, Wednesday, 22'nd Apr 2026
Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
07:02am, Wednesday, 22'nd Apr 2026
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more t
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
04:05pm, Tuesday, 21'st Apr 2026
SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therape
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
05:03pm, Monday, 20'th Apr 2026
– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT – SAN DIEGO, April 20, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives $150.00 Consensus Target Price from Analysts
01:09am, Tuesday, 14'th Apr 2026
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are presently covering the firm, MarketBeat.com reports. One investme
SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX
04:47am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commis
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
02:36am, Friday, 27'th Mar 2026
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will cont
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
04:00pm, Thursday, 19'th Mar 2026
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following
